Preclinical animal and in-vitro study

NMN Can Restore Ovarian Reserve in Aged Mice by Upregulating NAD+/SIRT1/PGC-1α Signaling Pathway and TOMM20 Expression, and Improve in Vitro Development of Aging Oocytes

Jing Wang et al. · Reproductive Sciences · 2026

Evidence type: Preclinical mechanistic study Interpretive weight: Mechanistic contextResearch area: Ovarian reserve and mitochondrial mechanisms
DesignPreclinical dose-ranging aged-mouse intervention plus in-vitro aged-oocyte culture experiments
PopulationAged female mice and aged mouse oocytes
SampleMultiple dose and control groups; see publication
InterventionNMN 200, 500, or 1,000 mg/kg/day for 10 days in aged mice; 1 µM NMN in selected oocyte-culture experiments
EndpointsOvarian follicle reserve; Ovarian NAD+ and ATP; Oocyte reactive oxygen species and apoptosis; Mitochondrial function; NAD+/SIRT1/PGC-1α signaling; TOMM20 expression; In-vitro oocyte developmental potential

What the publication reported

This 2026 preclinical study tested several NMN doses in aged female mice and examined ovarian reserve, mitochondrial biology and oocyte development.

The authors identified 500 mg/kg/day as the most effective tested dose for follicle-reserve measures. NMN increased ovarian NAD+ and ATP, reduced oxidative-stress and apoptosis markers, and altered SIRT1/PGC-1α/TOMM20-related mitochondrial pathways.

The study also reported improved development of aged mouse oocytes in culture. These are animal and in-vitro findings and do not establish fertility effects in women.

Key findings

  • NMN increased ovarian NAD+ and ATP in aged mice.
  • 500 mg/kg/day performed best among the tested in-vivo doses for follicle-reserve measures.
  • Oxidative-stress and apoptosis markers decreased while mitochondrial measures improved.
  • NAD+/SIRT1/PGC-1α signaling and TOMM20 were implicated.
  • In-vitro NMN improved developmental potential of aged mouse oocytes.

What it cannot establish

  • Mouse and in-vitro oocyte study only.
  • Short 10-day in-vivo exposure.
  • High animal doses are not directly translatable to human supplements.
  • No human ovarian-reserve, pregnancy or live-birth outcomes were tested.
HealthspanX claim boundary: This study does not establish that NMN restores ovarian reserve, fertility, egg quality or pregnancy outcomes in women.

Continue reviewing

Return to the complete evidence library.

Evidence Center Ultra Pure NMN

Source fields verified